—A Pharmacor Analyst Call from Decision Resources
Based on our Pharmacor Ovarian Cancer advisory service, Decision Resources is offering this exclusive analyst call entitled Ovarian Cancer: Avastin Will Revolutionize Therapeutic Options and Will Pave the Way for Targeted Therapy Approval. Because this analyst call will feature major findings, it is ONLY available to purchasers of this Pharmacor advisory service.
Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call.
Last month, the Committee for Medicinal Products for Human Use issued a positive recommendation for the European approval of Roche/Genentech/Chugai’s Avastin for the treatment of first-line advanced ovarian cancer. Decision Resources forecasts that Avastin will receive approval in Europe for this indication within the next few months. As a market currently devoid of targeted therapies, therapeutic options for ovarian cancer will be revolutionized by Avastin’s approval. Through 2020, Decision Resources forecasts growing therapeutic options for ovarian cancer as other targeted therapies gain approval in this increasingly dynamic market.
This 15-minute analyst call, presented by Decision Resources Analyst Amy Duval, M.Res, will answer the following questions:
- What are the advantages of adding Avastin to currently available cytotoxic agents used to treat advanced ovarian cancer?
- What is Decision Resources’ sales forecast through 2020 for Avastin and for the overall ovarian cancer drug market?
- Within the ovarian cancer market, how will other emerging therapies compete with currently available agents and Avastin, and how will treatment dynamics change over our forecast?
Ms. Duval will conduct a live Q & A session after the presentation.
Ovarian Cancer: Avastin Will Revolutionize Therapeutic Options and Will Pave the Way for Targeted Therapy Approvals
October 25, 2011 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris).
To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.
In North America | Keith Rourke | 781-993-2656
In Europe | Kaj van Langendonck | +32-2-357-06-14
In Japan | Makiko Yoshimoto | +81-3-5401-2615
Webinar Details Date & Time Duration: 15 minutes |
About the Speaker
|
Amy Duval, M.Res., is an oncology analyst at Decision Resources with expertise in ovarian cancer. Since joining the company, Ms. Duval has worked on a range of oncology indications, including breast cancer, pancreatic cancer and renal cell carcinoma. She has authored reports on small-cell lung cancer and non-small-cell lung cancer and has worked on topics in both the major and emerging pharmaceutical markets. Ms. Duval gained her B.Sc. in natural sciences and M.Res. in molecular and cellular biology from the University of Birmingham, where she conducted research into the epigenetics of leukemia.
Terms of Use | Privacy Policy | Contact Us | Careers
Decision Resources • 8 New England Executive Park • Burlington, MA 01803
You are receiving this email because you have previously requested information from Decision Resources. You can update your email preferences at any time.
© 2011 Decision Resources, LLC. All rights reserved.
